This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Me too. Have a good one people.

MS

I'm off shopping before the rush.. bye for now.

Shot-in-the-arm for firm

Success with an anti-cancer vaccine has almost quadrupled the value of Cambridge-based MMI since the beginning of the year, making the company worth 115 million.


Massive success: Founder David Best The biggest rise has come this week following results of clinical trials involving cancer patients suffering from lymphoma, but the new vaccine is expected to help with other forms of cancer as well, including lung.

The vaccine has been developed by Genvax. MMI owned 50 per cent, but this week increased its holding to 58 per cent.

The further investment comes as MMI's share price rockets yesterday it put on more than 38p, lifting to nearly 3. At the beginning of this year the shares were trading at under 60p.

The vaccine uses tetanus toxin to boost the immune response against cancer.

Known as a DNA fusion gene vaccine, it has been trialled on lymphoma patients for three years, with most responding well.

Patients with myeloma, cancer of the bone marrow, are now being given the vaccine, and the next in line are those suffering from prostate and colon cancer, and other solid tumours such as lung or stomach cancer.

Genvax has now clinched an exclusive worldwide licence with Cancer Research Technology to commercialise rights to the vaccine, which was invented by Prof Freda Stevenson at the University of Southampton.

MMI, which is based in Cowley Road, Cambridge, is putting more funds into Genvax to take the vaccine forward.

David Best, founder and boss of MMI, said: "Cancer is now the main cause of premature death in the western world.

"By working with the major cancer charities, the world class research team at the University of Southampton and the National Blood Service, together we now have the potential to improve the lives of patients with cancer and to keep the UK at the forefront of medicine."

MMI, which is listed on the London stock market, specialises in funding and commercialising breakthrough treatments developed within NHS hospital trusts.

24 March 2005

http://www.cambridge-news.co.uk/business/news/2005/03/24/2e2594a7-72b3-4155-bcc4-b2bd6aa76ed0.lpf

Saturdays Tipster from UK Analyst.

Keep Buying Medical Marketing

Suggests Zak Mir of Zaks-TA.com

It may sound strange, but there is nothing as difficult as trading or making a call on a stock or market that is rising vertically. Being in a steady uptrend when you can buy on dips, or sell on strength in a downtrend appears to be a piece of cake against situations where there are the most powerful moves. The best example of this at the moment is a stock called Medical Marketing. Being a chartist I am excused in knowing as little as possible about this stock. However, whatever you know about this company and the mega rally that it is experiencing, this will not really help you find a suitable entry point when the shares are flying around all over the place.

In fact, even from a charting perspective this situation is rather challenging one and obviously not for widows and orphans. The RSI reading on the daily chart is well over the traditional overbought zone of 70. However, if you had shorted the shares when they went over 70 you would be some 150p offside by now. The only satisfactory way of determining how high the stock could go is to attempt to draw the best fitting support and resistance lines. Years of experience have lead me to draw an upper parallel at 350p and this is the eventual target I am shooting for. As far as where to go long there is a gap between last Wednesday's high of 260p and the Thursday low of 267p and this is the best objective point to aim for currently.

cheers GF.

I reckon 350p is about right next week and 400p in about a months time these being my year end targets from 6 months ago.
Thereafter I would guess 700p.

What could be the opening price for mmg as the momentum is still upwards.

350p.

GF. How have you extrapolated the 350p resistance line.
Just interested?

Profit taking going on, no neeed to panic, taken the opportunity to add at 271p and 268p, buyers now moving back in and buying on the cheap.

chers GF.

bought in again at 273, thanks profit takers

I was a bit scared with a fall but holding in there,thanks to gf,instead added more at 272p.good luck everyone.

ateeq this is now a 300pence share, i think that is where it will be back at at the end of the day. rob

comparatively tight spread for mmg today......... will see a lot of day traders

Buyers coming back in droves. Really is a great opportunity to get a position in this one.

cheers GF.

LETS HOPE YOU R RIGHT,ITS NICE TO HAVE SOME GOOD INFORMATIVE PEOPLE ON THIS BOARD AS YOU MIGHT KNOW ON OTHER BOARDS PEOPLE ARE ONLY BLAMING EACH OTHER WHEN THE PRICE FALLS,AT THE END OF THE DAY WE SHOULD ALL LEARN TO ACCEPT THAT THE DECISION TO INVEST IN A COMPANY IS DOWN TO EACH INDIVIDUAL,SO WHEN THE PRICE IS SHOOTING WE SAY GOOD THINGS,BUT WHEN IT FALLS WE START BLAMING WHICH I FEEL IS WRONG.ANY WAY THANKS FOR ALL THE GOOD TIPS,AND KEEP UP THE GOOD WORK,AS I AM STILL LEARNING.

Added again at 273p. Might aswell wont get this opportunity again and the next big thing is just around the corner. Indications are that more trial results will be out during April. Ruthenium Compound results, could push this one through the 375p mark and more. Just a case of being patient.

cheers GF.

Added again at 273p. Might aswell wont get this opportunity again and the next big thing is just around the corner. Indications are that more trial results will be out during April. Ruthenium Compound results, could push this one through the 375p mark and more. Just a case of being patient.

cheers GF.

Price coming back in now. Early scare looks to be over.

cheers GF.

topped up at 275p.